Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P59 in outpatients with SARS-CoV-2 infection
2020-003369-20Phase 2Completed
- Sponsor
- Celltrion
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CT-P59 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary endpoint (Part 1). Started Sep 2020; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003369-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003369-20.